Ovarian Tissue Bioengineering for Fertility Preservation: Current Status and Future Prospects

Abstract

Ovarian tissue bioengineering has emerged as a transformative strategy in fertility preservation, particularly for women and girls at high risk of premature ovarian insufficiency due to cancer therapy or other gonadotoxic insults. This review synthesizes current evidence and clinical advances in ovarian tissue bioengineering, highlighting epidemiological trends, pathophysiological mechanisms, risk assessment, diagnostic approaches, and the latest bioengineering techniques. Emphasis is placed on clinically relevant outcomes, guideline-based management, and future directions, providing a comprehensive resource for healthcare professionals engaged in reproductive medicine.

Introduction

Fertility preservation is an increasingly critical aspect of patient care for individuals facing treatments or conditions that threaten reproductive potential. While oocyte and embryo cryopreservation have become mainstays, they are not universally applicable, particularly in prepubertal girls or patients requiring urgent intervention. Ovarian tissue cryopreservation (OTC) and subsequent transplantation represent a promising alternative, with bioengineering approaches aiming to overcome limitations of tissue viability, graft longevity, and malignant cell contamination. This article reviews the scientific and clinical landscape of ovarian tissue bioengineering, integrating recent advancements and evidence-based recommendations to inform practice.

Epidemiology / Disease Burden

The burden of infertility secondary to gonadotoxic therapies has grown in parallel with improved survival rates among cancer patients. It is estimated that up to 10% of reproductive-aged women with cancer are at risk of iatrogenic infertility, with higher rates in pediatric and adolescent populations. Non-malignant conditions such as autoimmune diseases and hematologic disorders requiring stem cell transplantation further expand the affected demographic. Globally, the demand for fertility preservation techniques is increasing, underscoring the need for accessible, effective, and safe solutions such as ovarian tissue bioengineering.

Pathophysiology

Ovarian tissue damage from chemotherapy, radiotherapy, or surgical intervention leads to depletion of the primordial follicle pool, stromal fibrosis, and compromised vascularization. The resultant premature ovarian insufficiency is characterized by hypoestrogenism and infertility. Bioengineering seeks to restore ovarian function by isolating, expanding, and transplanting viable follicles or engineered constructs, while mitigating ischemic injury and preserving the endocrine and reproductive capacity of the tissue. Scaffold-based and scaffold-free technologies, including the use of biomaterials and decellularized ovarian matrices, are central to current research.

Risk Factors

Key risk factors for ovarian insufficiency include the type, dose, and duration of gonadotoxic therapy, patient age at exposure, and underlying ovarian reserve. Genetic predispositions, such as BRCA mutations and Turner syndrome, confer additional risk. In the context of ovarian tissue bioengineering, the risk of malignant cell reintroduction is paramount, particularly in hematologic malignancies. Patient selection and individualized risk assessment are crucial for optimizing outcomes and minimizing complications.

Clinical Features

Clinically, ovarian insufficiency manifests as amenorrhea, infertility, vasomotor symptoms, and long-term sequelae such as osteoporosis and cardiovascular risks. Restoration of ovarian function through tissue transplantation is assessed by the return of menses, endocrine normalization, and the potential for natural conception. Monitoring for graft function, rejection, and recurrence of underlying disease is integral to post-procedural care.

Diagnosis

Assessment of ovarian reserve involves measurement of serum follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH), and antral follicle count via ultrasonography. Histological evaluation of ovarian cortical tissue confirms follicular density and viability. For patients at risk of metastatic disease, advanced molecular and immunohistochemical analyses are employed to detect minimal residual disease prior to tissue transplantation.

Treatment & Management

Ovarian tissue bioengineering encompasses tissue harvesting, cryopreservation, in vitro follicle maturation, and transplantation. Standard protocols involve laparoscopic retrieval of ovarian cortex, slow freezing or vitrification, and autotransplantation to orthotopic or heterotopic sites. Allografting and the use of engineered scaffolds are under investigation. Multidisciplinary management is essential, involving reproductive endocrinologists, oncologists, and tissue engineers to ensure safe and effective application of these techniques.

Recent Advances / Emerging Therapies

Recent innovations include the development of biocompatible hydrogels, 3D-printed scaffolds, and decellularized ovarian matrices to enhance follicle survival and function. In vitro activation of dormant follicles, combined with microfluidic systems for nutrient delivery, holds promise for improving graft longevity and reproductive outcomes. Gene editing and stem cell technologies are being explored for generating functional ovarian tissue de novo. Importantly, strategies to eliminate malignant contamination such as follicle isolation and artificial ovary construction are advancing the safety profile of ovarian tissue transplantation.

Guideline Recommendations

Current guidelines from the American Society for Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), and other bodies recommend ovarian tissue cryopreservation as a standard option for fertility preservation in select patient populations, particularly prepubertal girls and women unable to delay gonadotoxic therapy. Rigorous screening for malignant infiltration and individualized patient counseling are emphasized. Bioengineering approaches are recommended within clinical trials or specialized centers pending further evidence of safety and efficacy.

Conclusion

Ovarian tissue bioengineering represents a significant advance in fertility preservation, offering hope to patients otherwise facing irreversible infertility. Ongoing research continues to refine tissue viability, safety, and functional restoration, with multidisciplinary collaboration at the core of clinical success. As the field evolves, integration of bioengineering innovations into standard care will require robust clinical evidence, guideline development, and ethical considerations to ensure equitable access and optimal patient outcomes.